CA3194024A1 - Compounds and methods for treating viral infection - Google Patents

Compounds and methods for treating viral infection

Info

Publication number
CA3194024A1
CA3194024A1 CA3194024A CA3194024A CA3194024A1 CA 3194024 A1 CA3194024 A1 CA 3194024A1 CA 3194024 A CA3194024 A CA 3194024A CA 3194024 A CA3194024 A CA 3194024A CA 3194024 A1 CA3194024 A1 CA 3194024A1
Authority
CA
Canada
Prior art keywords
vitamin
derivative
acetyl glucosamine
infection
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3194024A
Other languages
English (en)
French (fr)
Inventor
Ameer E. HASSAN
Yousef Hasan Ahmad KHALILI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3194024A1 publication Critical patent/CA3194024A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CA3194024A 2020-09-04 2021-09-03 Compounds and methods for treating viral infection Pending CA3194024A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063074602P 2020-09-04 2020-09-04
US63/074,602 2020-09-04
US202163142669P 2021-01-28 2021-01-28
US63/142,669 2021-01-28
PCT/US2021/048991 WO2022051575A2 (en) 2020-09-04 2021-09-03 Compounds and methods for treating viral infection

Publications (1)

Publication Number Publication Date
CA3194024A1 true CA3194024A1 (en) 2022-03-10

Family

ID=80491477

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3194024A Pending CA3194024A1 (en) 2020-09-04 2021-09-03 Compounds and methods for treating viral infection

Country Status (7)

Country Link
US (1) US20230346816A1 (https=)
EP (1) EP4208137A4 (https=)
JP (1) JP2023541007A (https=)
CA (1) CA3194024A1 (https=)
MX (1) MX2023002667A (https=)
TW (1) TW202228730A (https=)
WO (1) WO2022051575A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2628963A (en) * 2023-02-08 2024-10-16 Univ Of Lincoln Formulations and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202239417A (zh) * 2021-01-29 2022-10-16 艾米爾 Ｅ 哈森 預防病毒感染之方法
CA3256512A1 (en) * 2022-04-21 2023-10-26 Therapeutikos, Inc. METHODS OF TREATING INFLAMMATION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533776A (zh) * 2003-03-27 2004-10-06 中国人民解放军第三军医大学 N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用
AU2006249771A1 (en) * 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
WO2011046057A1 (ja) * 2009-10-15 2011-04-21 独立行政法人産業技術総合研究所 シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物
JP5807895B2 (ja) * 2011-02-17 2015-11-10 学校法人慶應義塾 Ｈｃｖｒｎａ複製抑制剤
NZ732118A (en) * 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
CN107281199A (zh) * 2017-07-27 2017-10-24 吉林省始祖生物波医学研究院有限公司 N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2628963A (en) * 2023-02-08 2024-10-16 Univ Of Lincoln Formulations and uses thereof

Also Published As

Publication number Publication date
JP2023541007A (ja) 2023-09-27
MX2023002667A (es) 2023-05-12
WO2022051575A3 (en) 2022-04-07
EP4208137A2 (en) 2023-07-12
WO2022051575A2 (en) 2022-03-10
EP4208137A4 (en) 2024-08-28
US20230346816A1 (en) 2023-11-02
TW202228730A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
US20230346816A1 (en) Compounds and methods for treating viral infection
EP2848254B1 (en) Pyrazole derivative and use thereof for medical purposes
JP2024020274A (ja) ＳＡＲＳ－ＣｏＶ－２感染の治療における置換アミノプロピオン酸化合物の使用
WO2021195211A1 (en) Quinoline compounds for treating respiratory disorders and viral infections
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
RU2672871C2 (ru) Применение левоцетиризина и монтелукаста при лечении травматических повреждений
CN111686095A (zh) 大麻二酚在制备治疗冠状病毒感染的药物中的用途
CN119837879A (zh) 墨蝶呤及其代谢物治疗辐射暴露的用途
KR20260004440A (ko) 종양 괴사 인자 알파의 소분자 저해제를 사용한 건선 치료
US20240325386A1 (en) Therapeutic agent for covid-19
EP4129291A1 (en) Coronavirus infection treatment drug
EP3756660B1 (en) Medicament having anti-inflammatory bowel disease function, and preparation method therefor and application thereof
WO2017157248A1 (zh) 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
CN112870206B (zh) 甘露糖在制备预防脑型疟疾药物中的应用
CN112022858B (zh) 中药单体化合物组合在改善认知功能中的应用
WO2023034718A1 (en) Treatment of lower respiratory tract infection with tradipitant
CN112168831B (zh) 一个雷公藤内酯醇衍生物在防治炎症性肠病中的用途
WO2022165282A1 (en) Methods for preventing viral infection
Leal et al. Prospective, non-controlled pilot study to evaluate the efficacy and safety of Cefditoren Pivoxil in COVID-19 patients with mild to moderate pneumonia
EP4126054A1 (en) Methods for treating viral infections with nafamostat
TW201622715A (zh) 治療自發性肺纖維化之方法
RU2491550C1 (ru) Способ прогнозирования развития респираторных болезней у новорожденных телят
CHOWDHURY et al. A case report of clinical outcome of a COVID-19 patient presented by acute ischemic stroke
CN121890566A (zh) 一种构建矽肺相关性动脉粥样硬化动物模型的方法
WO2025033134A1 (ja) 炎症性サイトカイン発現抑制剤及び炎症性サイトカイン発現を抑制する方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260218